Stockscreener 앱 받기
54.08
3.36%
-1.88
시간 외 거래:
54.08
전일 마감가:
$55.96
열려 있는:
$56.1
하루 거래량:
793.22K
Relative Volume:
0.51
시가총액:
$7.81B
수익:
-
순이익/손실:
$-946.53M
주가수익비율:
-7.763
EPS:
-6.9664
순현금흐름:
$-814.94M
1주 성능:
-1.06%
1개월 성능:
-6.97%
6개월 성능:
+0.95%
1년 성능:
+59.29%
1일 변동 폭
$53.53
$56.39
1주일 범위
$52.47
$57.03
52주 변동 폭
$29.08
$65.00
백스사이트 Stock (PCVX) Company Profile
명칭
Vaxcyte Inc
전화
650-837-0111
주소
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
54.08 | 8.01B | 0 | -946.53M | -814.94M | -6.9664 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
백스사이트 Stock (PCVX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재확인 | Needham | Buy |
| 2025-09-12 | 개시 | Goldman | Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-20 | 개시 | Goldman | Buy |
| 2023-12-07 | 개시 | Mizuho | Buy |
| 2023-04-18 | 개시 | TD Cowen | Outperform |
| 2023-01-03 | 재확인 | Needham | Buy |
| 2022-12-15 | 개시 | Guggenheim | Buy |
| 2022-11-17 | 개시 | BTIG Research | Buy |
| 2021-12-29 | 재개 | Jefferies | Buy |
| 2021-06-24 | 재개 | Jefferies | Buy |
| 2020-07-07 | 개시 | BofA Securities | Buy |
| 2020-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-07-07 | 개시 | Needham | Buy |
모두보기
백스사이트 주식(PCVX)의 최신 뉴스
Grant Pickering (PCVX) outlines 18,198-share sale and recent June stock trades - Stock Titan
PCVX|Vaxcyte Inc|Price:55.720|Chg%:+1.060 - TradingKey
Vaxcyte Inc (PCVX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vaxcyte Inc (PCVX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TradingKey - TradingKey
Vaxcyte Inc (PCVX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Vaxcyte Inc (PCVX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vaxcyte Inc (PCVX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vaxcyte Inc (PCVX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vaxcyte Inc (PCVX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PCVX|Vaxcyte Inc|Price:55.535|Chg%:+0.875 - TradingKey
Is Vaxcyte's VAX-31 a Game-Changer in the Vaccine Landscape - Kavout | AI
Enterprise value to revenue forward of Vaxcyte, Inc. – BX:PCVX - TradingView
Vaxcyte, Inc. Revenue Breakdown – NASDAQ:PCVX - TradingView
ETFs Investing in Vaxcyte, Inc. Stocks - TradingView
Vaxcyte: Clinical-Stage Vaccine Disrupter With Vast Near-Term Potential - Seeking Alpha
Vaxcyte stock consolidates after raising fresh capital and advancing PCVX vaccine pipeline - Ad-hoc-news.de
MSN Money - MSN
Why (PCVX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Vaxcyte Director John Markels Awarded 23,029 Stock Options in July 2026 Equity Grant - Kalkine Media
Form 4 Vaxcyte Inc For: 16 July By Investing.com - Investing.com Nigeria
Vaxcyte, Inc. (PCVX) awards 23,029 stock options to director John Markels - Stock Titan
Vaxcyte, Inc. (PCVX) director files Form 3 reporting zero holdings - Stock Titan
Vaxcyte (NASDAQ: PCVX) adds independent director John Markels, sets $430,000 equity grant - Stock Titan
Guggenheim Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $116 - Moomoo
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring an 87% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Vaxcyte Inc. (PCVX) Slides 2.71%, Approaches Key Support at $55.3IV Spike - dars.gov.et
Vaxcyte Inc. (PCVX) Sees Modest Pullback After Recent Rally – Key Support Levels in FocusMcClellan Oscillator - dars.gov.et
Vaxcyte to Participate in Upcoming Investor Conferences - Investing News Network
Vaxcyte Inc develops next-generation vaccines as interest in pneumococcal prevention grows - ad-hoc-news.de
Should Early VAX-A1 Trial Progress Require Action From Vaxcyte (PCVX) Investors? - simplywall.st
Vaxcyte Inc. (PCVX) Surges 6.5% as Vaccine Developer Attracts Renewed Investor InterestIceberg Order - dars.gov.et
Vaxcyte COO Jim Wassil sells $126,736 in PCVX shares By Investing.com - Investing.com Australia
Vaxcyte president and CFO sells $572k in company stock By Investing.com - Investing.com Australia
Vaxcyte president and CFO sells $572k in company stock - Investing.com
Form 4 Vaxcyte Inc For: 6 July By Investing.com - Investing.com Nigeria
[Form 4] Vaxcyte, Inc. Insider Trading Activity - Stock Titan
Vaxcyte COO Jim Wassil sells $126,736 in PCVX shares - Investing.com
Vaxcyte (PCVX) COO logs 2,250-share sale and option exercise in Form 4 - Stock Titan
Affiliate plans 10,000-share sale by option exercise — PCVX - Stock Titan
Vaxcyte, Inc. (PCVX) Stock Analysis: Biotechnology Innovator with an 86.68% Potential Upside - DirectorsTalk Interviews
PCVXVaxcyte Inc Volatility & Greeks - Finviz
Vaxcyte stock stays tied to pipeline progress. Nasdaq listing and SEC filings frame the setup. - Ad-hoc-news.de
Vaxcyte Inc (PCVX) Is A Hidden Multibagger Stock To Buy Now - Yahoo Finance
Vaxcyte Inc. (PCVX) Surges 4% as Vaccine Developer Gains MomentumGap Down Bounce Plays - dars.gov.et
Have Insiders Sold Vaxcyte Shares Recently? - simplywall.st
백스사이트 (PCVX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
백스사이트 주식 (PCVX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER |
Jul 27 '26 |
Sale |
55.63 |
16,198 |
901,069 |
453,247 |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER |
Jul 27 '26 |
Sale |
55.65 |
2,000 |
111,307 |
133,215 |
2.44%
0.02%
자본화:
|
볼륨(24시간):